Top

Published in:

01-11-2020 | Osteoporosis | Review Article

Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis

Authors: Sara Kaveh, Hossein Hosseinifard, Nashmil Ghadimi, Mahdi Vojdanian, Aidin Aryankhesal

Published in: Clinical Rheumatology | Issue 11/2020

Abstract

Osteoporosis is a chronic skeletal disease with an increasing prevalence. Romosozumab, as a monoclonal anti-sclerostin antibody with a dual function, has been produced. In this meta-analysis, we aimed to examine the efficacy of Romosozumab in patients with low bone mineral density. A systematic search was conducted in the most important electronic search engines like Cochrane Library, PubMed, Web of Science, Scopus, Google Scholar, and ClinicalTrials.gov at the end of July 2019 to retrieve randomized controlled trials (RCTs), which evaluated the effect of Romosozumab in patients with osteoporosis and/or low bone mineral density. After evaluating the quality of articles with the Cochrane checklist, data related to the outcomes of bone mineral density (BMD) of lumbar spine, femoral neck, and total hip, risk of clinical, vertebral and non-vertebral fractures, and risk of adverse events were extracted. Quality of evidence was assessed according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Heterogeneity between studies was evaluated by I2 and Q statistics. The meta-analysis was performed using CMA v.2.0 software. Of all the 671 initially retrieved articles, seven articles were entered into the meta-analysis after removing duplicates and reviewing papers with inclusion and exclusion criteria. The results of the meta-analysis showed that Romosozumab 210, 140, and 70 mg compared with Alendronate, Teriparatide, and placebo can increase the bone mineral density in the lumbar spine, femoral neck, and total hip. The risk of adverse events like adjudicated cardiovascular serious adverse events and adjudicated cardiovascular death was more in Romosozumab 210 mg in comparison with placebo. However, this difference was not statistically significant. Treatment with anti-sclerostin antibodies can be a proper therapeutic option in patients with osteoporosis and low bone mineral density. Based on the results of this meta-analysis, it seems that Romosozumab, with its dual function, has a positive role in the treatment of osteoporosis and low bone mineral density.

Available only for authorised users

Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26(12):2773–2783. https://doi.org/10.1007/s00198-015-3234-7CrossRefPubMedPubMedCentral

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276–1287. https://doi.org/10.1016/s0140-6736(10)62349-5CrossRefPubMedPubMedCentral

Kling JM, Clarke BL, Sandhu NP (2014) Osteoporosis prevention, screening, and treatment: a review. J Women's Health (Larchmt) 23(7):563–572. https://doi.org/10.1089/jwh.2013.4611CrossRef

Amelio P, Isaia GC (2015) Male osteoporosis in the elderly. Int J Endocrinol 2015:8. https://doi.org/10.1155/2015/907689CrossRef

Bello MO, Garla VV (2019) Osteoporosis in males. In: StatPearls [internet]. StatPearls Publishing

Orive M, Aguirre U, Garcia-Gutierrez S, Las Hayas C, Bilbao A, Gonzalez N, Zabala J, Navarro G, Quintana JM (2015) Changes in health-related quality of life and activities of daily living after hip fracture because of a fall in elderly patients: a prospective cohort study. Int J Clin Pract 69(4):491–500. https://doi.org/10.1111/ijcp.12527CrossRefPubMed

Vergara I, Vrotsou K, Orive M, Gonzalez N, Garcia S, Quintana JM (2014) Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. BMC Geriatr 14:124. https://doi.org/10.1186/1471-2318-14-124CrossRefPubMedPubMedCentral

Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95(3):1174–1181. https://doi.org/10.1210/jc.2009-0852CrossRefPubMed

Ettinger MP (2003) Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 163(18):2237–2246. https://doi.org/10.1001/archinte.163.18.2237CrossRefPubMed

10.

Lewiecki EM (2010) Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 1(3):115–128. https://doi.org/10.1177/2040622310374783CrossRefPubMedPubMedCentral

11.

Tella SH, Gallagher JC (2014) Biological agents in management of osteoporosis. Eur J Clin Pharmacol 70(11):1291–1301CrossRefPubMed

12.

Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D (2018) Osteoporosis: a review of treatment options. P T 43(2):92–104PubMedPubMedCentral

13.

Becker CB (2014) Sclerostin inhibition for osteoporosis--a new approach. N Engl J Med 370(5):476–477. https://doi.org/10.1056/NEJMe1315500CrossRefPubMed

14.

Costa AG, Bilezikian JP, Lewiecki EM (2014) Update on romosozumab: a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther 14(5):697–707. https://doi.org/10.1517/14712598.2014.895808CrossRefPubMed

15.

McClung MR (2017) Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis 9(10):263–270. https://doi.org/10.1177/1759720x17726744CrossRefPubMedPubMedCentral

16.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543. https://doi.org/10.1056/NEJMoa1607948CrossRefPubMed

17.

Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209–215. https://doi.org/10.1016/j.bone.2017.07.005CrossRefPubMed

18.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427. https://doi.org/10.1056/NEJMoa1708322CrossRefPubMed

19.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585–1594. https://doi.org/10.1016/s0140-6736(17)31613-6CrossRefPubMed

20.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183–3193. https://doi.org/10.1210/jc.2017-02163CrossRefPubMed

21.

Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21(2):189–195. https://doi.org/10.1080/13697137.2018.1433655CrossRefPubMed

22.

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937. https://doi.org/10.1002/jbmr.2202CrossRefPubMed

23.

Vidal M, Thibodaux RJ, Neira LFV, Messina OD (2019) Osteoporosis: a clinical and pharmacological update. Clin Rheumatol 38(2):385–395. https://doi.org/10.1007/s10067-018-4370-1CrossRefPubMed

24.

Glasser SP, Duval S (2014) Meta-analysis, evidence-based medicine, and clinical guidelines. In: Essentials of Clinical Research. Springer, pp 203–231

25.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

26.

Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions, vol 4. Wiley

27.

Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Bossuyt P, Chang S, Muti P, Jaeschke R, Guyatt GH (2008) GRADE: assessing the quality of evidence for diagnostic recommendations. BMJ Evid Based Med 13(6):162–163CrossRef

28.

Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta-analyses. In: Cochrane handbook for systematic reviews of interventions, pp 241–284

29.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420. https://doi.org/10.1056/NEJMoa1305224CrossRefPubMed

30.

MacNabb C, Patton D, Hayes JS (2016) Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges. J Osteoporos 2016:6217286. https://doi.org/10.1155/2016/6217286CrossRefPubMedPubMedCentral

31.

Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, Brown JP, Langdahl BL, Yan C, Grauer A, Libanati C (2017) Greater gains in spine and hip strength for Romosozumab compared with Teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32(9):1956–1962. https://doi.org/10.1002/jbmr.3176CrossRefPubMed

32.

Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ (2017) Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone 95:20–25. https://doi.org/10.1016/j.bone.2016.11.009CrossRefPubMed

33.

Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48(4):798–803. https://doi.org/10.1016/j.bone.2010.12.006CrossRefPubMed

34.

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C (2017) Effects of Romosozumab compared with Teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181–187. https://doi.org/10.1002/jbmr.2932CrossRefPubMed

35.

Matheny JB, Torres AM, Ominsky MS, Hernandez CJ (2017) Romosozumab treatment converts trabecular rods into trabecular plates in male Cynomolgus monkeys. Calcif Tissue Int 101(1):82–91. https://doi.org/10.1007/s00223-017-0258-3CrossRefPubMed

36.

Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32(4):788–801. https://doi.org/10.1002/jbmr.3036CrossRefPubMed

37.

Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, Jang G (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54(2):168–178. https://doi.org/10.1002/jcph.239CrossRefPubMed

38.

NCT02791516 (2018) A safety and efficacy study to evaluate romosozumab (AMG 785) in South Korean women with osteoporosis. https://ClinicalTrials.gov/show/NCT02791516. Accessed 23 July 2019

39.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026CrossRefPubMed

40.

FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture (2019) FDA. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635653.htm. Accessed 10 April 2019

41.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537–543. https://doi.org/10.1093/hmg/10.5.537CrossRefPubMed

42.

Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, Yuan FZ, Guo C, Yan SG (2012) Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 66(4):399–408. https://doi.org/10.1111/j.1742-1241.2011.02806.xCrossRefPubMed

43.

Beaudoin C, Moore L, Gagne M, Bessette L, Ste-Marie LG, Brown JP, Jean S (2019) Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression. Osteoporos Int 30(4):721–740. https://doi.org/10.1007/s00198-019-04919-6CrossRefPubMed

44.

Rubin KH, Abrahamsen B, Friis-Holmberg T, Hjelmborg JV, Bech M, Hermann AP, Barkmann R, Gluer CC, Brixen K (2013) Comparison of different screening tools (FRAX(R), OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone 56(1):16–22. https://doi.org/10.1016/j.bone.2013.05.002CrossRefPubMed

Title: Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
Authors: Sara Kaveh
Hossein Hosseinifard
Nashmil Ghadimi
Mahdi Vojdanian
Aidin Aryankhesal
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keywords: Osteoporosis
Osteoporosis
Published in: Clinical Rheumatology / Issue 11/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04948-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies

Orofacial manifestations of SAPHO syndrome: a systematic review of case reports

Facial necrotic ulcerative lesions in an adolescent female with granulomatosis with polyangiitis (GPA)

Mitochondrial DNA in osteoarthritis disease

Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study

Role of cell autophagy in the generation of IgM and hepatic fibrosis in primary biliary cholangitis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page